{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-020623","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.799300+00:00","generated_at":"2026-06-14T03:55:25.074712+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncocyte enters amended CEO employment agreement with Joshua Riggs; grants 1.15M options","bullets":["Base salary $360,000, target bonus 50% of base salary, effective May 1, 2023.","CEO Grant: options to purchase 350,000 shares, 25% vests at 1 year, balance monthly over 3 years.","Performance Grant: options for 800,000 shares, vesting tied to VWAP targets ($0.54-$1.08) by Dec 31, 2025.","Severance includes 12 months base salary, pro-rated bonus, health premium if terminated without cause or for good reason.","Riggs appointed CEO Feb 24, 2023; this agreement amends and restates prior agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-020623","json":"https://secwatch.observer/filing/0001493152-23-020623.json","markdown":"https://secwatch.observer/filing/0001493152-23-020623.md","text":"https://secwatch.observer/filing/0001493152-23-020623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/0001493152-23-020623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:55:25.074712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a93f5b7b9","claim":"Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/0001493152-23-020623-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}